Biomarkers

Biomarkers Market Research Reports & Consulting

Market Reports

Title	Published	Price	TOC Available
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022 The biobanking market is expected to reach USD 2.69 Billion by 2022 from USD 1.72 Billion in 2016 at a CAGR of 7.8%. The base year for this study is 2016. The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.)	August 2017	$ 5650
Vital Signs Monitoring Market - Landscape Analysis of Blood Pressure Monitoring Devices, Pulse Oximeters and Temperature Monitoring Devices - Forecasts up to 2018 The word “vital” connotes the most significant requirement for sustaining healthy life. Blood pressure, respiratory rate, heart rate and body temperature within a normal range are necessary for the survival of human life and these parameters are referred to as vital signs.	August 2013	$ 5650

Title

Published

Price

TOC Available

Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood Products, Human Tissues, Cell Lines, Nucleic Acids), Application( Regenerative Medicine, Life Science, Clinical Research) - Global Forecast to 2022

The biobanking market is expected to reach USD 2.69 Billion by 2022 from USD 1.72 Billion in 2016 at a CAGR of 7.8%. The base year for this study is 2016. The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.)

August 2017

$ 5650

Vital Signs Monitoring Market - Landscape Analysis of Blood Pressure Monitoring Devices, Pulse Oximeters and Temperature Monitoring Devices - Forecasts up to 2018

The word “vital” connotes the most significant requirement for sustaining healthy life. Blood pressure, respiratory rate, heart rate and body temperature within a normal range are necessary for the survival of human life and these parameters are referred to as vital signs.

August 2013

$ 5650